USFDA inspection at Jaggaiahpet API facility ends with Form 483, 5 observations

Regulatory & Legal View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹436.40

prior close

₹439.50

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.0%+5.0% vs market

Pharmaceuticals peers, median of 174sector+0.2%+4.8% vs sector

On the reaction day the stock moved 5.0 pts more than Nifty Smallcap 250 and 4.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.1

15m

+0.4

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0-0.0+5.0+0.2+4.8

Next day

+3.8-0.1+3.9+0.1+3.7

+5.9+0.7+5.3+1.0+4.9

+4.0-0.7+4.7-0.1+4.0

+5.1-0.7+5.8+0.0+5.1

+4.1-2.3+6.4-0.5+4.6

+1.6-2.7+4.3-1.0+2.6

15d

-0.1-2.5+2.4-4.5+4.5

+5.7-6.8+12.6-7.4+13.1

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences announced completion of a USFDA inspection at its API manufacturing facility in Jaggaiahpet, Andhra Pradesh, held from September 14 to 19, 2026. The inspection ended with a Form FDA 483 containing five observations. The company has started corrective and preventive actions and will submit its response within the stipulated timeline. Cohance reaffirmed its commitment to quality and regulatory compliance.

Likely market impact

Minor regulatory observations; short-term price impact possible pending USFDA acceptance of CAPA response